Register now!
Login
OCTOBER 11-12, 2024
Fondazione Cariplo - Conference Center
MILAN, ITALY
Scientific Program
On this page you will find the Scientific Program of the Delta...
| Opening Session | |
| 11.20-11.30 | Welcome by Chairs P. Lampertico and H. Wedemeyer |
| WHO session | Hepatitis Delta: making a difference in low- and middle-income countries Moderator: F.P. Russo |
| 11.30-11.40 | Updated WHO HBV guidelines and recommendations for testing and diagnosis for HDV N. Luhmann |
| 11.40-11.50 | Diagnostics for HDV: what we have and what we need for improving diagnosis in low- and-middle income countries I. Chemin |
| 11.50-12.00 | Hepatitis Delta epidemiology and experiences with HDV diagnosis and reflex testing in Uzbekistan E. Musabaev |
| 12.00-12.15 | HDV diagnosis and treatment in Pakistan and the way forward for LMICs S.S. Hamid |
| 12.15-12.30 | Panel discussion |
| 12.30-13.30 | Light Lunch and poster viewing |
| Session 1 | Virology and Pathogenesis Moderators: M. Dandri and J. Lucifora |
| 13.30-13.50 | Virology: the latest insights S. Urban |
| 13.50-14.10 | Pathogenesis: insights from liver biopsies L. Allweiss |
| 14.10-14.30 | Are immune responses important in HDV infection? H. Kefalakes |
| 14.30-14.50 | New HBV biomarkers: any role in HDV? B. Testoni |
| 14.50-15.00 | Oral presentation (selected Abstract) |
| 15.00-15.20 | Discussion |
| 15.20-15.50 | Coffee Break and poster viewing |
| Session 2 | Diagnosis, Staging, HCC risk and antiviral therapy Moderators: S. Aleman and R. Esteban |
| 15.50-16.10 | HDV-RNA assays: performances and clinical challenges M.P. Anolli |
| 16.10-16.30 | Fibroscan and other non-invasive markers L. Sandmann |
| 16.30-16.50 | PegIFN+NUC: predictors of response M. Brunetto |
| 16.50-17.00 | Oral presentation (selected abstract) |
| 17.00-17.20 | Discussion |
| Session 3 | Current and new antiviral treatments I Moderators: G. Papatheodoridis and N. Reau |
| 17.20-17.40 | Bulevirtide mono and combo in clinical trials H. Wedemeyer |
| 17.40-17.55 | Bulevirtide in EU: SAVE-D study update E. Degasperi |
| 17.55-18.10 | Bulevirtide in France: multicenter study update H. Fontaine |
| 18.10-18.25 | Bulevirtide for decompensated cirrhosis M. Jachs |
| 18.25-18.35 | Oral presentation (selected abstract) |
| 18.35-19.00 | Discussion |
| 19.00-19.30 | State of the Art Lecture and Prize: “My journey with HDV” C. Yurdaydin (presented by H. Wedemeyer) |
| 19.30-20.00 | Transfer to the Dinner venue (walking distance) |
| 20.00-22.30 | Apero and Dinner |
| 08.30-08.50 | Opening remarks Day 2 P. Lampertico and H. Wedemeyer |
| Session 4 | Current and new antiviral treatments II Moderators: T. Berg and M. Buti |
| 08.50-09.10 | Bulevirtide in HIV coinfected patients G. D’Offizi |
| 09.10-09.30 | Can we stop Bulevirtide? Lessons learned from viral kinetics modelling H. Dahari |
| 09.30-09.50 | What have we learned from the Lonafarnib and pegIFN lambda trials? T. Asselah |
| 09.50-10.10 | New antivirals for HDV, phase II studies K. Agarwal |
| 10.10-10.30 | What can we learn from HBV trials for HDV cure? F. Zoulim |
| 10.30-10.40 | Oral presentation (selected abstract) |
| 10.40-11.00 | Discussion |
| 11.00-11.30 | Coffee Break and poster viewing |
| Session 5 | Round Table Discussion Moderators: P. Lampertico and H. Wedemeyer |
| 11.30 -12.30 | Hot topics in HDV management. Academia, Pharma, Diagnostics, Patient Associations |
| 12.30-12.45 | Closing remarks P. Lampertico and H. Wedemeyer |
| 12.45-13.45 | Farewell Light Lunch |
